Mind-NRG Company
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain.
NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
Connections
Headquarters:
Geneva, Geneve, Switzerland, Europe
Founded Date:
2010-01-01
Industry:
Drug Discovery & Development
Employee Number:
1-10
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 22 737 00 00
Investors:
Index Ventures, Limburgse Reconversie Maatschappij
Ipo Status:
private
City:
Geneva
Region:
Geneve
Country:
Switzerland
Founders:
Gage Tarrant